Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamada Provides Update on 2021 GLASSIA Supply to Takeda","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Kamada"},{"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Kamada"},{"company":"Medison Pharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Medison Pharma Sign Distribution Agreement for Myalepta\u00ae (metreleptin) in Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Medison Pharma"},{"company":"Medison Pharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Medison Pharma"}]

Medison Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

Details:

Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahepatic cholestasis.

Lead Product(s): Odevixibat

Therapeutic Area: Genetic Disease Product Name: Bylvay

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Albireo Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 16, 2022

ASK
US

Upload
your Pipeline Activity

Kamada

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue ...

Details:

GLASSIA, is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1 -PI, also known as alpha1 -antitrypsin deficiency.

Lead Product(s): Alpha1-Proteinase Inhibitor

Therapeutic Area: Genetic Disease Product Name: Glassia

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2022

ASK
US

Upload
your Pipeline Activity

Medison Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Details:

This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.

Lead Product(s): Metreleptin

Therapeutic Area: Genetic Disease Product Name: Myalepta

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Amryt Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 08, 2021

ASK
US

Upload
your Pipeline Activity

Kamada

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kamada Provides Update on 2021 GLASSIA Supply to Takeda

Details:

Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.

Lead Product(s): Alpha1-Proteinase Inhibitor (Human)

Therapeutic Area: Genetic Disease Product Name: Glassia

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Agreement October 07, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY